- Gout flare (77%)

- Infusion reaction (26%)

- Nausea (12%)

- Contusion or ecchymosis (11%)

- Nasopharyngitis (7%)

- Constipation (6%)

- Chest Pain (6%)

- Anaphylaxis (5%)

- Vomiting (5%)

- CHF exacerbation (2%)

The adverse effects were reported from randomized, double-blind placebo-controlled clinical trials in subjects receiving pegloticase at 8 mg dosage every two weeks.

**US-Boxed Warning**

- Anaphylaxis

- Infusion reactions

- G6PD deficiency (hemolysis and methemoglobinemia)